Third Wave Completes HPV Clinical Trial Enrollment
MADISON, Wis., Dec. 31, 2007– Third Wave Technologies Inc. (NASDAQ: TWTI) today announced that the company has achieved the subject enrollment goals for its HPV-products clinical trial.
The total enrollment target was comprised of 2,000 normal subjects and 1,400 women with atypical, or ASCUS, Pap test results. The next steps in the clinical trial include obtaining the final colposcopy...
